In 2016, the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) evaluated the non-inferiority of a lower dose of IV tPA (0.6 mg/kg) compared to the standard dose (0.9 mg/kg) (36). This evidence concerns the gene PLAT and Stroke.